Business
Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board
Salt Lake City, Utah--(Newsfile Corp. - February 1, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced today the
About this update from Kiora Pharmaceuticals, Inc.
[{"type":"text","content":"Salt Lake City, Utah--(Newsfile Corp. - February 1, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (\"Kiora\" or the \"Company\") announced today the appointment of Erin Parsons as a new independent Director of its Board of Directors (the \"Board\"). Separately, the Executive Chairman, Stephen From, has informed Kiora of his voluntary resignation from the Board. These changes are effective immediately.\n\"I am pleased to welcome Erin Parsons to our Board of Directors,\" said Brian M. Strem, Ph.D, President and CEO of Kiora. \"Erin brings extensive commercial and strategic expertise in eyecare, a critical and complementary perspective as we continue to dedicate efforts to develop therapeutics for eventual commercial successes.\"\n\"This is an exciting time to join Kiora's Board,\" said Erin Parsons. \"Their pipeline includes KIO-301, a photo-switching small molecule drug that has the potential to restore vision in blindness caused by retinal degeneration. This could be game-changing to patients suffering from a rare form of blindness called Retinitis Pigmentosa. Additionally, KIO-101, a proven next-generation anti-inflammatory may provide a novel approach to addressing ocular surface disease in rheumatoid arthritis patients. I look forward to working with the entire Board and leadership team to further advance these promising therapeutics.\"\nErin Parsons' extensive knowledge, experience, and network in the eyecare industry bring to the Company a broad understanding of the unmet needs in ophthalmic diseases in the front and back of the eye. During her career, she participated in the commercialization of XIIDRA®, OXERVATE®, LUCENTIS®, BEOVU®, DUREZOL®, ZIRGAN®, among others. In 2010 she founded Parsons Medical Communications where she currently serves as President. This leading agency provides scientific and strategic consulting to small and large companies in the ophthalmic space. Click here to read her full bio.\nStephen From served as Kiora's Executive Chairman since early 2021, and previously served as Kiora's (under the former name of EyeGate Pharmaceuticals, Inc.) President, CEO and Director since 2005. Kiora's Board accepted Stephen From's voluntary resignation to pursue other activities. Paul Chaney, Kiora's current Lead Independent Director, will be assuming the role of Chairman of the Board.\n\"On behalf of the Comp...